Tropifexor

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Non Alcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis

Phase 2

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

TerminatedNCT04065841

Novartis PharmaceuticalsNon Alcoholic Steatohepatitis (NASH)

Start: 2019-12-30End: 2022-10-27Updated: 2025-01-28

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)

TerminatedNCT04147195

Novartis PharmaceuticalsNon-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis

Start: 2020-06-04End: 2022-01-06Updated: 2023-08-21

Related Papers

Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis.

2025-11-26

NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.

2025-01-019 citations

From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis

Clinical Liver Disease2023-01-132 citations